CAS
ANAB icon

Coppell Advisory Solutions’s AnaptysBio ANAB Stock Holding History

Coppell Advisory Solutions’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-714
Closed -$17.9K – 1878
2024
Q2 		$17.9K Buy
+714
New +$16.6K ﹤0.01% 834

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coppell Advisory Solutions's ANAB Position: Q3 2024 in Review

Coppell Advisory Solutions sold out of AnaptysBio (ANAB) in Q3 2024, closing a stake of 714 shares — an estimated $17.9K sold.

Coppell Advisory Solutions first reported a position in ANAB in Q2 2024 and held it in 1 quarter. The position peaked at $17.9K in Q2 2024. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2024.

  • Coppell Advisory Solutions reported no remaining AnaptysBio position as of Q3 2024 after selling out during the quarter.
  • Coppell Advisory Solutions sold 714 AnaptysBio shares in Q3 2024, an estimated $17.9K.
  • Coppell Advisory Solutions first reported a position in AnaptysBio in Q2 2024 and held it in 1 quarter.
  • Coppell Advisory Solutions's AnaptysBio position peaked at $17.9K in Q2 2024.
  • 160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2024.

Based on Coppell Advisory Solutions's 13F filing for Q3 2024, filed 14 Nov 2024.